[go: up one dir, main page]

FI971310L - 2,7-substituoituja oktahydro-1H-pyrido/1,2-a/pyratsiinijohdannaisia - Google Patents

2,7-substituoituja oktahydro-1H-pyrido/1,2-a/pyratsiinijohdannaisia Download PDF

Info

Publication number
FI971310L
FI971310L FI971310A FI971310A FI971310L FI 971310 L FI971310 L FI 971310L FI 971310 A FI971310 A FI 971310A FI 971310 A FI971310 A FI 971310A FI 971310 L FI971310 L FI 971310L
Authority
FI
Finland
Prior art keywords
pyrido
pyrazine derivatives
substituted octahydro
octahydro
substituted
Prior art date
Application number
FI971310A
Other languages
English (en)
Swedish (sv)
Other versions
FI971310A0 (fi
FI113655B (fi
Inventor
Kishor A Desai
Anton F J Fliri
Mark A Sanner
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of FI971310L publication Critical patent/FI971310L/fi
Publication of FI971310A0 publication Critical patent/FI971310A0/fi
Application granted granted Critical
Publication of FI113655B publication Critical patent/FI113655B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI971310A 1994-09-30 1997-03-27 2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia FI113655B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US31547094A 1994-09-30 1994-09-30
US31547094 1994-09-30
IB9500689 1995-08-24
PCT/IB1995/000689 WO1996010571A1 (en) 1994-09-30 1995-08-24 2,7-SUBSTITUTED OCTAHYDRO-1H-PYRIDO[1,2-a]PYRAZINE DERIVATIVES

Publications (3)

Publication Number Publication Date
FI971310L true FI971310L (fi) 1997-03-27
FI971310A0 FI971310A0 (fi) 1997-03-27
FI113655B FI113655B (fi) 2004-05-31

Family

ID=23224581

Family Applications (1)

Application Number Title Priority Date Filing Date
FI971310A FI113655B (fi) 1994-09-30 1997-03-27 2,7-aryylisubstituoituja oktahydro-1H-pyrido[1,2-a]pyratsiinijohdannaisia

Country Status (34)

Country Link
US (1) US5852031A (fi)
EP (1) EP0783503B1 (fi)
JP (1) JP3287574B2 (fi)
KR (1) KR100244848B1 (fi)
CN (1) CN1068327C (fi)
AT (1) ATE209648T1 (fi)
AU (1) AU681310B2 (fi)
BR (1) BR9504230A (fi)
CA (1) CA2200959C (fi)
CO (1) CO4410335A1 (fi)
CZ (1) CZ285090B6 (fi)
DE (1) DE69524241T2 (fi)
DK (1) DK0783503T3 (fi)
ES (1) ES2166830T3 (fi)
FI (1) FI113655B (fi)
HR (1) HRP950507B1 (fi)
HU (1) HUT77354A (fi)
IL (1) IL115384A (fi)
MX (1) MX9702350A (fi)
MY (1) MY113729A (fi)
NO (1) NO308995B1 (fi)
NZ (1) NZ290936A (fi)
PE (1) PE47196A1 (fi)
PL (1) PL180899B1 (fi)
PT (1) PT783503E (fi)
RU (1) RU2163239C2 (fi)
SI (1) SI9520096A (fi)
SK (1) SK284341B6 (fi)
TR (1) TR199501194A2 (fi)
TW (1) TW406081B (fi)
UA (1) UA50720C2 (fi)
WO (1) WO1996010571A1 (fi)
YU (1) YU63795A (fi)
ZA (1) ZA958223B (fi)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6231833B1 (en) * 1999-08-05 2001-05-15 Pfizer Inc 2,7-substituted octahydro-1H-pyrido[1,2-A]pyrazine derivatives as ligands for serotonin receptors
US6992188B1 (en) 1995-12-08 2006-01-31 Pfizer, Inc. Substituted heterocyclic derivatives
JP3204456B2 (ja) * 1995-12-21 2001-09-04 ファイザー・インコーポレーテッド ２，７―置換オクタヒドロ―ピロロ［１，２―ａ］ピラジン誘導体
US6281216B1 (en) * 1998-02-09 2001-08-28 Duphar International Research B.V. 2-aminoquinoline derivatives having d4-agonistic activity
EP0953567A3 (en) 1998-04-29 2003-04-02 Pfizer Products Inc. Bicyclic substituted piperazine-, piperidine- and tetrahydropyridine derivatives, their preparation and their use as agents with central dopaminergic (dopamine D4 receptor) activity
GT199900060A (es) * 1998-05-22 2000-10-14 Polimorfos de un monoclorhidrato de pirazina cristalino y sus composiciones farmacèuticas.
GB0010757D0 (en) 2000-05-05 2000-06-28 Astrazeneca Ab Chemical compounds
GB0011013D0 (en) * 2000-05-09 2000-06-28 Astrazeneca Ab Chemical compounds
EP1177792A3 (en) 2000-07-27 2002-10-23 Pfizer Products Inc. Dopamine D4 Ligands for the treatment of novelty-seeking disorders
US6670476B2 (en) 2000-11-29 2003-12-30 Pfizer Inc. Resolution of trans-7-(hydroxy-methyl)octa-hydro-2H-pyrido[1,2-a]pyrazine
GB0121941D0 (en) 2001-09-11 2001-10-31 Astrazeneca Ab Chemical compounds
EP1479676A1 (en) * 2003-05-19 2004-11-24 Aventis Pharma Deutschland GmbH Benzimidazole-derivatives as factor xa inhibitors
US7244734B2 (en) * 2003-09-26 2007-07-17 Solvay Pharmaceuticals B.V. Hexa- and octahydro-pyrido[1,2-a]pyrazine derivatives with NK1 antagonistic activity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3388128A (en) * 1965-09-03 1968-06-11 Allan R. Day Substituted 1, 4-diazabicyclo [4. 4. 9] decanes
US4182763A (en) * 1978-05-22 1980-01-08 Mead Johnson & Company Buspirone anti-anxiety method
US4517187A (en) * 1982-10-18 1985-05-14 Pennwalt Corporation 1,3,4,6,7-11b-Hexahydro-7-phenyl-2H-pyrazino[2,1-a]isoquinolines methods of preparation, and use as antidepressants
EP0173634B1 (fr) * 1984-08-07 1988-08-31 Cortial S.A. Nouveaux dérivés d'(arylpipérazinyléthylaminoéthoxy)-4 phénol, leur méthode de préparation et leur application thérapeutique
US4704390A (en) * 1986-02-13 1987-11-03 Warner-Lambert Company Phenyl and heterocyclic tetrahydropyridyl alkoxy-benzheterocyclic compounds as antipsychotic agents
IT1204803B (it) * 1986-02-17 1989-03-10 Acraf Composto farmacologicamente attivo e composizioni farmaceutiche che lo contengono,procedimento per prepararlo e intermedio utile in detto procedimento
US4788290A (en) * 1987-12-11 1988-11-29 American Home Products Corporation Serotonergic pyrazine derivatives
SE8803429D0 (sv) * 1988-09-28 1988-09-28 Pharmacia Ab Novel pyridyl- and pyrimidyl derivatives
WO1990008148A1 (en) * 1989-01-23 1990-07-26 Pfizer Inc. Bis-aza-bicyclic anxiolytic agents
JP2609410B2 (ja) * 1991-01-31 1997-05-14 ファイザー・インコーポレーテッド （７Ｓ，トランス）−２−（２−ピリミジニル）−７−（ヒドロキシメチル）オクタヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジンの製造
US5157034A (en) * 1991-02-27 1992-10-20 Pfizer Inc. Neuroleptic perhydro-1H-pyrido[1,2-a]pyrazines
US5185449A (en) * 1991-02-27 1993-02-09 Pfizer Inc. Process and intermediate for certain bis-aza-bicyclic anxiolytic agents
EP0573464B1 (en) * 1991-02-27 1997-03-19 Pfizer Inc. Process for preparing trans-piperidine-2,5-dicarboxylates
AU655071B2 (en) * 1991-09-25 1994-12-01 Pfizer Inc. Neuroleptic 2-substituted perhydro-1-H-pyrido(1,2a) pyrazines
CA2138018C (en) * 1992-06-16 1998-01-27 Frank J. Urban Process and intermediates for bis-aza-bicyclic anxiolytic agents
WO1994010145A1 (en) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
CA2146018A1 (en) * 1992-10-23 1994-05-11 Paul David Leeson Dopamine receptor subtype ligands
BR9406128A (pt) * 1993-03-01 1996-02-27 Merck Sharp & Dohme Uso de um composto processo para o tratamento e/ou prevençao de distúrbios psicóticos composto composiçao farmacêutica processos para a preparaçao de um composto e de uma composiçao farmacêutica
EP0687267B1 (en) * 1993-03-01 1999-09-01 MERCK SHARP & DOHME LTD. Pyrrolo-pyridine derivatives as ligands of dopamine receptor
US5576319A (en) * 1993-03-01 1996-11-19 Merck, Sharp & Dohme Ltd. Pyrrolo-pyridine derivatives
CA2156409A1 (en) * 1993-03-05 1994-09-15 Janusz Jozef Kulagowski Quinolone derivatives as dopamine d4 ligands
GB9416162D0 (en) * 1994-08-10 1994-09-28 Merck Sharp & Dohme Therapeutic agents

Also Published As

Publication number Publication date
CZ285090B6 (cs) 1999-05-12
SK32597A3 (en) 1998-09-09
AU681310B2 (en) 1997-08-21
CN1068327C (zh) 2001-07-11
NO971416D0 (no) 1997-03-25
EP0783503A1 (en) 1997-07-16
PL319636A1 (en) 1997-08-18
MY113729A (en) 2002-05-31
PT783503E (pt) 2002-03-28
DK0783503T3 (da) 2002-02-11
ATE209648T1 (de) 2001-12-15
IL115384A (en) 1999-10-28
IL115384A0 (en) 1995-12-31
HUT77354A (hu) 1998-03-30
PE47196A1 (es) 1996-11-11
DE69524241D1 (de) 2002-01-10
CO4410335A1 (es) 1997-01-09
FI971310A0 (fi) 1997-03-27
US5852031A (en) 1998-12-22
TR199501194A2 (tr) 1996-06-21
CN1168672A (zh) 1997-12-24
JP3287574B2 (ja) 2002-06-04
YU63795A (sh) 1999-03-04
NO971416L (no) 1997-05-20
WO1996010571A1 (en) 1996-04-11
TW406081B (en) 2000-09-21
RU2163239C2 (ru) 2001-02-20
CA2200959A1 (en) 1996-04-11
AU3189395A (en) 1996-04-26
ZA958223B (en) 1997-04-01
KR100244848B1 (ko) 2000-03-02
SI9520096A (sl) 1998-04-30
ES2166830T3 (es) 2002-05-01
NZ290936A (en) 1998-01-26
HRP950507A2 (en) 1997-08-31
MX9702350A (es) 1997-06-28
KR970706282A (ko) 1997-11-03
UA50720C2 (uk) 2002-11-15
BR9504230A (pt) 1996-08-06
HRP950507B1 (en) 2002-06-30
DE69524241T2 (de) 2002-06-13
JPH09511527A (ja) 1997-11-18
CZ94797A3 (cs) 1998-07-15
CA2200959C (en) 2000-05-23
NO308995B1 (no) 2000-11-27
EP0783503B1 (en) 2001-11-28
FI113655B (fi) 2004-05-31
SK284341B6 (sk) 2005-02-04
PL180899B1 (pl) 2001-04-30

Similar Documents

Publication Publication Date Title
NO974595D0 (no) Imidazo£1,2-a|pyridin-derivater
FI962155L (fi) Uudet 9-hydroksipyrido (1,2-a) pyrimidin-4-onieetterijohdannaiset
DK0934320T3 (da) Naphthyridinderivater
DE69804273D1 (de) 5h-Thiazolo[3,2-a]pyrimidinderivate
DE69529777D1 (de) 2-Benzylthio-8-amino(1,2,4)triazolo(1,5-a)pyridine
FI952424L (fi) 11,21-bisfenyyli-19-norpregaanijohdannaisia
FI971310L (fi) 2,7-substituoituja oktahydro-1H-pyrido/1,2-a/pyratsiinijohdannaisia
ATE205846T1 (de) 2,7-substituierte octahydropyrrolo(1,2- a)pyrazinderivate
DE69502542D1 (de) 2-Phenyl-7-chlor-perhydroimidazo(1,5-a)pyridine
MA23504A1 (fr) Derives de la 1,5 benzodiazepine
BR9701675A (pt) Novos pirimido(1,2-a)indóis
DE69524611D1 (de) Pyrimidon-derivate
FI20000354L (fi) Perhydro-1H-pyrido/1,2-a/pyratsiinijohdannaiset
FI923290A7 (fi) Imidatso(2,1-b)bentsotiatsoli-3-asetamidijohdannaisia
FI971193L (fi) Hoidossa käyttökelpoisia kinoksaliinijohdannaisia
DE69714358D1 (de) 9,10-disubstituierte campothecinderivate mit antitumoraktivität
FI943999A7 (fi) Pyrido(1,2,3-d,e)(1,3,4)bentsoksadiatsiinijohdannaisia
TR28915A (tr) Naftokinon türevleri.
DE69515498D1 (de) Naphthyridinderivate
NO993024D0 (no) Polysakkarid-peptid-derivater
DE69722064D1 (de) 1,25-Dihydroxy-16,22,23-trisdehydro-Cholecalciferol-Derivate
FI970827A7 (fi) Uudet tiatsolo 3,2-a/kinoliini - ja -nafthyridiinijohdannaiset
FI961199A7 (fi) Substituoidut tiatsolo(3,2-alfa)atsepiinijohdannaiset
DE69411093D1 (de) Pyrazin-derivate

Legal Events

Date Code Title Description
MA Patent expired